Neoprobe shares jump on US FDA submission for cancer diagnostic agent
This article was originally published in Clinica
Executive Summary
Shares of Neoprobe soared as high as 13.6% on 11 August after the firm submitted its new drug application (NDA) to the US FDA for its radioactive diagnostic tracing agent Lymphoseek (tilmanocept). The tracer is used in intraoperative lymphatic mapping (ILM), a surgical oncology procedure used primarily in patients with breast cancer and melanoma to determine if disease has spread to the lymph nodes.